Purity vs grade
“99.4% pure” is not a grade.
A purity number and a manufacturing standard are two different claims. Vendors let you hear them as one, because that gap is where this market does its selling. Here is the difference in plain English, and the one question that settles it.
What is in the vial
One lab took one sample, once, and measured how much of it was the peptide. That is the entire claim. It is a photograph of a sample, and the sample is not the batch.
How it was made
The room. The equipment and when it was last calibrated. Who was trained, and on what. What was cleaned between batches. Which records exist, and who signed them. A certificate cannot see any of it.
Purity and grade are different questions. A lab test says what is in the vial; it cannot say the vial was filled in a controlled facility. Almost everything sold here is research-use-only material.
The two do not move together. A very high number can come out of an uncontrolled room. A controlled facility can report an ordinary one. So when a number is offered as the answer to “is this well made,” the question has been quietly swapped.
The three words
Only one of them means anything on its own
These three get used as if they were rungs on one ladder. They are not. Two are descriptions of intent, and one is a regulation about a building.
Layer 1
“Research use only”
A sentence about intended use. Not a quality tier.
What it is
A line the seller prints on the label saying the contents are not meant for people. That is the whole of it.
What it is not
A grade. There is no purity bar a product has to clear to be called “research use only,” no inspection behind it, and no one checking. Two vials with the same disclaimer can be nothing alike.
How to test it
Ask what standard it was made to, and who verified that. There is no standard behind the phrase, and a candid vendor will tell you so. The label is also not a shield: the FDA has told peptide sellers in writing that a “research use only” statement did not change what their products were — the letter is in the sources below.
Where you meet it
Essentially every listing on VialGrade sits here.
Layer 2
“Pharmaceutical grade”
A marketing phrase, unless a certificate is attached.
What it is
A phrase with real pull and no fixed meaning of its own. The terms that carry weight in US drug law are specific and nameable: meeting a USP or NF monograph, being made in a facility registered with the FDA, and being made under GMP.
What it is not
It is not a classification anyone assigns or certifies. You can check this yourself in about a minute: the phrase appears nowhere in Title 21 of the Code of Federal Regulations, the part of US law that covers food and drugs. Search the entire CFR for it and you get 14 results — every one of them in the EPA’s air-pollution rules.
How to test it
Ask which of the three they mean, and ask for the paperwork. A vendor who means something specific will name it. A vendor who means nothing will answer with a purity number — which is the other question entirely.
Where you meet it
Watch for it in the fine print near a big purity figure.
Layer 3
GMP
A real standard about the building, not the batch.
What it is
Good Manufacturing Practice — federal regulations covering the methods, facilities and controls used to make a drug. In plain terms: the rooms, the equipment, the staff, the incoming materials, the records, and who is allowed to sign off.
What it is not
Not something a lab report can establish. A certificate looks at a sample after the fact; GMP is about what happened in the building before the sample existed.
How to test it
Ask for the certificate and the name of the body that issued it, and ask whether it covers the finished vial or a raw ingredient bought from someone else. Those are very different claims.
Where you meet it
Vanishingly rare in this market. Treat a bare “GMP” badge with no document as decoration.
Compounded is a fourth thing
A pharmacy is not a website
If you have seen a clinic or telehealth service offer a peptide, that is compounding — a licensed pharmacy making a drug for a named patient. It is a separate legal lane from a site that ships a vial to anyone. It is worth understanding, because the vendor language borrows from it.
A state-licensed pharmacy
Day-to-day oversight sits mainly with state boards of pharmacy. The FDA says plainly that drugs compounded this way are not subject to GMP requirements.
An outsourcing facility
A category created in 2013. These register with the FDA, are inspected by the FDA on a risk-based schedule, and are subject to GMP. This is the stricter of the two.
The line the FDA draws, which is this whole page in one rule
For a pharmacy to compound with a bulk substance, the FDA requires two separate things: a valid certificate of analysis, and that the substance was made by an establishment registered with the FDA. The paper is not accepted in place of the facility. That is the same distinction a vendor collapses when a purity number is offered as proof of quality.
Where the well-known peptides actually stand
The FDA keeps a public list of bulk substances it has flagged as possibly presenting significant safety risks in compounding — “category 2.” On 29 September 2023 it added several peptide substances, including GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10. For a substance in category 2, the FDA says it would consider taking action against a compounder who used it.
A larger group — among them BPC-157, CJC-1295, TB-500, MOTS-c, semax, epitalon, selank, melanotan II, GHK-Cu for injection, LL-37 and AOD-9604 — appears on the same FDA page in a second table, of substances that were previously in category 2 and whose nominations were then withdrawn by the people who filed them. Withdrawn is not the same as cleared. None of these is on the 503A list a pharmacy may compound from.
And it is still moving. On 23–24 July 2026 the FDA’s Pharmacy Compounding Advisory Committee met to discuss whether BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax and epitalon should go on that list.
This section has a shelf life. It was checked against the FDA’s own pages on 14 August 2026. Before you rely on any of it, open the sources at the bottom and look for yourself — and note that none of this is about whether a peptide is safe. It is about what a licensed pharmacy is permitted to make.
What to actually do
Ask. Then read the shape of the answer.
You cannot inspect a factory. You can send a message and watch what comes back. A real answer is specific and checkable — including when the answer is no. A dodge answers a question you did not ask.
“Is this GMP? Can I see the certificate and who issued it?”
A real answer
A certificate naming a facility and an issuing body — or a straight “no, this is research material and we don’t claim GMP.” A clean no is a good answer. It is honest and it is checkable.
A dodge
“Our purity meets pharmaceutical standards.” That answers a different question. Also watch for “our supplier is GMP” — which supplier, for which step, and does it cover the vial you would receive?
“Who picked the vial that was tested?”
A real answer
A sealed retail unit sent in, or a third-party blind purchase. The vendor did not choose which one went to the lab.
A dodge
“We test every batch,” with no word on where the sample came from. A vendor-chosen sample is the vendor’s best vial, and you are not buying that vial.
“What batch number is that certificate for, and is it the batch I’d receive?”
A real answer
A batch number you can match to the label on the vial that arrives.
A dodge
One undated certificate reused across every product, or a batch number that appears nowhere on what ships.
“Was anything besides purity tested?”
A real answer
Naming what was tested and what wasn’t — sterility and endotoxin are separate tests and usually were not run.
A dodge
Answering with the purity number again, as though clean and pure were the same word.
“Which lab, and can they confirm they issued this?”
A real answer
A named lab with a way to verify the report independently.
A dodge
A PDF with a logo and no route back to the lab. Anyone can make one of those.
A good answer is still only an answer
A vendor who answers all five well has told you they are careful and candid. That is worth a great deal and it is not the same as proof. Nothing on this page, and nothing a vendor says, makes any product safe to put in your body — VialGrade never claims that about anything.
Check it yourself
Five lookups, free, no account
None of these will tell you a product is safe. They will tell you whether a specific claim is true, which is a different and more useful thing.
Is that facility registered?
The FDA publishes its register of drug establishments and updates it every business day. If a vendor names the facility that made something, look it up. Being listed tells you the establishment is registered — that, and nothing more.
Is that pharmacy a 503B?
A separate FDA list, because the register above deliberately leaves outsourcing facilities out. It shows each one’s last inspection — and a lot of rows say “Not yet inspected.” Registering is something a facility elects to do; it is not a pass mark.
Has the FDA flagged this compound?
The category 2 page lists what the FDA has flagged for compounding, with the specific concern written out for each substance. It is readable without a science degree.
Is that accreditation real?
A2LA, one of the bodies that accredits testing labs, publishes a running list of companies caught claiming its accreditation without holding it — including a supplement brand whose test report carried the A2LA symbol without permission.
Has this vendor been written to?
Public FDA warning letters, import alerts, DOJ and FTC actions against sellers in this market — the ones we track, each with its source document linked.
Sources
Every rule above, and where it came from
Primary documents only — the regulations themselves and the FDA’s own pages. Checked 14 August 2026. If one of these has moved since, the source wins and this page is wrong.
- 1
Current Good Manufacturing Practice regulations — 21 CFR Part 210
Electronic Code of Federal Regulations
GMP is defined as the minimum practice for the methods, facilities and controls used to make a drug — not as a property of a finished sample.
https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210 - 2
CGMP for finished pharmaceuticals — 21 CFR Part 211
Electronic Code of Federal Regulations
What GMP actually covers, subpart by subpart: personnel, buildings and facilities, equipment, incoming components, production controls, packaging, holding, laboratory controls, and records.
https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211 - 3
Full-text search of the Code of Federal Regulations for “pharmaceutical grade”
Electronic Code of Federal Regulations (search API)
That the phrase appears nowhere in Title 21 (Food and Drugs). It returns 14 results across the whole CFR, all of them under Title 40, the EPA’s air programs.
https://www.ecfr.gov/api/search/v1/counts/hierarchy?query=%22pharmaceutical+grade%22 - 4
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
U.S. Food and Drug Administration (page current as of 14 May 2026)
What a compounding pharmacy may use, the requirement for both a valid certificate of analysis and an FDA-registered manufacturing establishment, and the definition of category 2.
https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act - 5
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
U.S. Food and Drug Administration (page current as of 22 April 2026)
The category 2 table and its dates, and the separate table of substances previously in category 2 that were withdrawn by their nominators.
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks - 6
Meeting of the Pharmacy Compounding Advisory Committee, 23–24 July 2026
U.S. Food and Drug Administration
The agenda naming BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax and epitalon as substances being considered for the 503A bulks list.
https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 - 7
Compounding and the FDA: Questions and Answers
U.S. Food and Drug Administration (page current as of 16 September 2025)
The difference between 503A pharmacies and 503B outsourcing facilities, who inspects each, and which of the two is subject to CGMP.
https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers - 8
Warning letter to Gram Peptides, 31 March 2026 (MARCS-CMS 721806)
U.S. Food and Drug Administration
The FDA stating that a “Research Use Only” label did not change what the products were, where the seller’s own marketing showed they were intended as drugs for people. The FDA cautions that a warning letter reflects the situation at the time it was issued and the status may have changed since — check the letter for a closeout.
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026 - 9
Drug Establishments Current Registration Site (DECRS)
U.S. Food and Drug Administration
The public, daily-updated register of drug establishments — where anyone can check whether a named facility is registered with the FDA. The FDA notes on the same page that this register does not include compounding outsourcing facilities, which is why the next source exists.
https://www.fda.gov/drugs/drug-approvals-and-databases/drug-establishments-current-registration-site-decrs - 10
Registered Outsourcing Facilities
U.S. Food and Drug Administration (list updated 10 August 2026)
The separate list of 503B facilities, with each one’s last inspection date, whether a Form 483 was issued, and whether a recall was conducted — including the many rows reading “Not yet inspected.”
https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities - 11
False Claims of Accreditation
A2LA (accreditation body for testing laboratories)
A published, dated list of companies claiming A2LA accreditation without holding it — including a product whose promoted test report used the A2LA symbol without authorization.
https://portal.a2la.org/search/falseclaims.cfm
Keep going
The rest of the picture
The real benchmark
The regulated manufacturers whose peptides go into approved medicines — the bar everything else is measured against.
How we check
What a lab test proves, the six questions one report answers, and what we refuse to guess.
Lab reports
Every certificate we hold, what it establishes, and what stays unknown.
The law around this
How research peptides are regulated in the US, in plain English.
General information, not legal or medical advice. VialGrade sells nothing, recommends nothing, and encourages no human use. Nothing here says any product is safe, sterile, correctly dosed, or fit to use.